Literature DB >> 25036774

Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision.

Cheng-Ming Chiang1.   

Abstract

The tandem bromodomains (BD1 and BD2) of the BET family proteins BRD2, BRD3, BRD4, and BRDT are structurally conserved but not functionally equivalent. In this issue of Chemistry & Biology, Gacias and colleagues report that a BD1-specific chemical inhibitor, Olinone, enhances oligodendrocyte differentiation, contrasting the reverse process triggered by broad BD1/BD2-targeting inhibitors, highlighting distinct roles of BD1 and BD2 in cell fate decision.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25036774      PMCID: PMC4137397          DOI: 10.1016/j.chembiol.2014.07.003

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  10 in total

1.  Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression.

Authors:  Mar Gacias; Guillermo Gerona-Navarro; Alexander N Plotnikov; Guangtao Zhang; Lei Zeng; Jasbir Kaur; Gregory Moy; Elena Rusinova; Yoel Rodriguez; Bridget Matikainen; Adam Vincek; Jennifer Joshua; Patrizia Casaccia; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2014-06-19

2.  Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3.

Authors:  Roland Gamsjaeger; Sarah R Webb; Janine M Lamonica; Andrew Billin; Gerd A Blobel; Joel P Mackay
Journal:  Mol Cell Biol       Date:  2011-05-09       Impact factor: 4.272

Review 3.  The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.

Authors:  Shwu-Yuan Wu; Cheng-Ming Chiang
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

4.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.

Authors:  Jian Shi; Yifan Wang; Lei Zeng; Yadi Wu; Jiong Deng; Qiang Zhang; Yiwei Lin; Junlin Li; Tiebang Kang; Min Tao; Elena Rusinova; Guangtao Zhang; Chi Wang; Haining Zhu; Jun Yao; Yi-Xin Zeng; B Mark Evers; Ming-Ming Zhou; Binhua P Zhou
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

5.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.

Authors:  Shwu-Yuan Wu; A-Young Lee; Hsien-Tsung Lai; Hong Zhang; Cheng-Ming Chiang
Journal:  Mol Cell       Date:  2013-01-11       Impact factor: 17.970

6.  Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.

Authors:  Z Zou; B Huang; X Wu; H Zhang; J Qi; J Bradner; S Nair; L-F Chen
Journal:  Oncogene       Date:  2013-05-20       Impact factor: 9.867

7.  The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.

Authors:  Antje Dittmann; Thilo Werner; Chun-Wa Chung; Mikhail M Savitski; Maria Fälth Savitski; Paola Grandi; Carsten Hopf; Matthew Lindon; Gitte Neubauer; Rabinder K Prinjha; Marcus Bantscheff; Gerard Drewes
Journal:  ACS Chem Biol       Date:  2013-12-10       Impact factor: 5.100

8.  Histone recognition and large-scale structural analysis of the human bromodomain family.

Authors:  Panagis Filippakopoulos; Sarah Picaud; Maria Mangos; Tracy Keates; Jean-Philippe Lambert; Dalia Barsyte-Lovejoy; Ildiko Felletar; Rudolf Volkmer; Susanne Müller; Tony Pawson; Anne-Claude Gingras; Cheryl H Arrowsmith; Stefan Knapp
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

9.  Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.

Authors:  Stuart W J Ember; Jin-Yi Zhu; Sanne H Olesen; Mathew P Martin; Andreas Becker; Norbert Berndt; Gunda I Georg; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2014-03-13       Impact factor: 5.100

10.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Authors:  Pietro Ciceri; Susanne Müller; Alison O'Mahony; Oleg Fedorov; Panagis Filippakopoulos; Jeremy P Hunt; Elisabeth A Lasater; Gabriel Pallares; Sarah Picaud; Christopher Wells; Sarah Martin; Lisa M Wodicka; Neil P Shah; Daniel K Treiber; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2014-03-02       Impact factor: 15.040

  10 in total
  11 in total

Review 1.  Epigenetic modifications-insight into oligodendrocyte lineage progression, regeneration, and disease.

Authors:  Alexander Gregath; Qing Richard Lu
Journal:  FEBS Lett       Date:  2018-02-22       Impact factor: 4.124

2.  BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression.

Authors:  Shwu-Yuan Wu; Dawn Sijin Nin; A-Young Lee; Scott Simanski; Thomas Kodadek; Cheng-Ming Chiang
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

3.  Opposing Functions of BRD4 Isoforms in Breast Cancer.

Authors:  Shwu-Yuan Wu; Chien-Fei Lee; Hsien-Tsung Lai; Cheng-Tai Yu; Ji-Eun Lee; Hao Zuo; Sophia Y Tsai; Ming-Jer Tsai; Kai Ge; Yihong Wan; Cheng-Ming Chiang
Journal:  Mol Cell       Date:  2020-05-23       Impact factor: 17.970

Review 4.  Chromatin remodeling and epigenetic regulation of oligodendrocyte myelination and myelin repair.

Authors:  Elijah Koreman; Xiaowei Sun; Q Richard Lu
Journal:  Mol Cell Neurosci       Date:  2017-12-15       Impact factor: 4.314

Review 5.  Phospho-BRD4: transcription plasticity and drug targeting.

Authors:  Cheng-Ming Chiang
Journal:  Drug Discov Today Technol       Date:  2016-07-18

6.  Conditional Human BRD4 Knock-In Transgenic Mouse Genotyping and Protein Isoform Detection.

Authors:  Michael Paul Lewis; Shwu-Yuan Wu; Cheng-Ming Chiang
Journal:  Bio Protoc       Date:  2022-04-05

7.  Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.

Authors:  Qianqian Wang; Ying Li; Jiahui Xu; Yuwei Wang; Elaine Lai-Han Leung; Liang Liu; Xiaojun Yao
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

8.  The C-terminal low-complexity domain involved in liquid-liquid phase separation is required for BRD4 function in vivo.

Authors:  Chenlu Wang; Erhao Zhang; Fan Wu; Yufeng Sun; Yingcheng Wu; Baorui Tao; Yue Ming; Yuanpei Xu; Renfang Mao; Yihui Fan
Journal:  J Mol Cell Biol       Date:  2019-09-19       Impact factor: 6.216

9.  Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.

Authors:  Michael D Olp; Daniel J Sprague; Christopher J Goetz; Stefan G Kathman; Sarah L Wynia-Smith; Shifali Shishodia; Steven B Summers; Ziyang Xu; Alexander V Statsyuk; Brian C Smith
Journal:  ACS Chem Biol       Date:  2020-03-23       Impact factor: 5.100

Review 10.  Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.

Authors:  Carles Galdeano; Alessio Ciulli
Journal:  Future Med Chem       Date:  2016-05-19       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.